Chart: FDA’s ANDA Approvals
FDA's ANDA Approvals
You may also be interested in...
Apotex subsidiary Torpharm's diltiazem extended-release capsules approved May 20 in 120 mg, 180 mg, 240 mg, and 300 mg strengths. Reference listed drug is Biovail's Cardizem CD (1"The Pink Sheet" May 24, 2004, p. 38)...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials